Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2254558 |
| _version_ | 1797690160172761088 |
|---|---|
| author | Tahsin Anwar Sean Malhotra Mohammad A. H. Mian Tahiya Anwar Vamsi Kota Mahran Shoukier |
| author_facet | Tahsin Anwar Sean Malhotra Mohammad A. H. Mian Tahiya Anwar Vamsi Kota Mahran Shoukier |
| author_sort | Tahsin Anwar |
| collection | DOAJ |
| first_indexed | 2024-03-12T01:55:34Z |
| format | Article |
| id | doaj.art-c3363f8980354162b060c61cfdff423d |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-12T01:55:34Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-c3363f8980354162b060c61cfdff423d2023-09-08T06:16:41ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2254558Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trialsTahsin Anwar0Sean Malhotra1Mohammad A. H. Mian2Tahiya Anwar3Vamsi Kota4Mahran Shoukier5Augusta University, Augusta, GeorgiaEmory University, Atlanta, GeorgiaAugusta University Medical Center, Augusta, GeorgiaAugusta University Medical Center, Augusta, GeorgiaAugusta University, Augusta, GeorgiaMedical College of Georgia, Augusta University, Augusta, Georgiahttps://www.tandfonline.com/doi/10.1080/16078454.2023.2254558 |
| spellingShingle | Tahsin Anwar Sean Malhotra Mohammad A. H. Mian Tahiya Anwar Vamsi Kota Mahran Shoukier Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials Hematology |
| title | Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials |
| title_full | Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials |
| title_fullStr | Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials |
| title_full_unstemmed | Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials |
| title_short | Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials |
| title_sort | industry s role in hiv hepatitis b and hepatitis c exclusion in aml and mds clinical trials |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2254558 |
| work_keys_str_mv | AT tahsinanwar industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials AT seanmalhotra industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials AT mohammadahmian industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials AT tahiyaanwar industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials AT vamsikota industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials AT mahranshoukier industrysroleinhivhepatitisbandhepatitiscexclusioninamlandmdsclinicaltrials |